Effects of hCG-to-oocyte retrieval interval on oocyte performances in women with polycystic ovary syndrome undergoing progestin-primed ovarian stimulation: a retrospective cohort trial

人绒毛膜促性腺激素(hCG)注射至取卵间隔对接受孕激素预处理促排卵的多囊卵巢综合征患者卵子性能的影响:一项回顾性队列研究

阅读:1

Abstract

PURPOSE: To investigate the optimal interval time between hCG and oocyte retrieval in polycystic ovary syndrome (PCOS) women undergoing progestin-primed ovarian stimulation (PPOS). METHODS: This retrospective cohort study included a total of 537 PCOS women undergoing PPOS cycles between January 2021 and July 2023 at a university-affiliated reproductive center. Patients were divided into three groups according to the quartiles of post-trigger intervals (Q1:36.0-36.60 h; Q2-3: 36.61-37.20 h; Q4: 37.21-38.0 h). The oocyte performances and pregnancy outcomes were compared among the three intervals. RESULTS: The number of mature oocytes in the Q4 group was increased compared to the other two groups (15.20 ± 7.87 vs. 12.43 ± 6.35 vs. 13.86 ± 7.46, P < 0.05), but the mature oocyte yield from follicles > 10 mm on the trigger day was comparable among the three groups (64.47 ± 27.18% vs. 63.18 ± 24.95% vs. 63.34 ± 25.54%, P > 0.05). The comparison of live birth outcomes was found no significant difference among the three groups (69.6% vs. 65.9% vs. 75.8%, P > 0.05). CONCLUSION: The prolongation of the time intervals between hCG and oocyte retrieval from 36.0 to 38.0 h in PPOS cycles did not show an obvious improvement in terms of oocyte performances and pregnancy outcomes in the PCOS women. More well-designed prospective trials are necessary to verify the benefits and risks of prolonged intervals in PPOS cycles in the PCOS women. TRIAL REGISTRATION: No available.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。